Diabetes Type 1

Metabolic Diseases
1
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY900014Phase 34 trials
Active Trials
NCT03433677Completed49Est. Sep 2018
NCT03341312Completed36Est. Mar 2018
NCT03341299Completed36Est. Apr 2018
+1 more trials
Sanofi
SanofiPARIS, France
1 program
insulin Glargine + Insulin ApidraN/A1 trial
Active Trials
NCT00925977Terminated44Est. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eli Lilly and CompanyLY900014
Eli Lilly and CompanyLY900014
Eli Lilly and CompanyLY900014
Eli Lilly and CompanyLY900014
Sanofiinsulin Glargine + Insulin Apidra

Clinical Trials (5)

Total enrollment: 194 patients across 5 trials

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes

Start: Feb 2018Est. completion: Sep 201849 patients
Phase 3Completed

A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)

Start: Nov 2017Est. completion: Mar 201836 patients
Phase 1Completed

A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus

Start: Nov 2017Est. completion: Apr 201836 patients
Phase 1Completed

A Study of LY900014 Formulations in Healthy Participants

Start: Jan 2015Est. completion: Sep 201529 patients
Phase 1Completed
NCT00925977Sanofiinsulin Glargine + Insulin Apidra

Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents

Start: Jul 2009Est. completion: Feb 201244 patients
N/ATerminated

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space